...
首页> 外文期刊>Journal of Obstetrics and Gynecology of India >A Retrospective Case–Control Study Evaluating the Role of Mifepristone for Induction of Labor in Women with Previous Cesarean Section
【24h】

A Retrospective Case–Control Study Evaluating the Role of Mifepristone for Induction of Labor in Women with Previous Cesarean Section

机译:回顾性病例对照研究评估米非司酮在剖宫产前妇女引产中的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Objective To investigate the role of “mifepristone” for induction of labor (IOL) in pregnant women with prior cesarean section (CS). Methods In this retrospective study, all pregnant women with prior CS who received oral mifepristone (400?mg) for IOL (as per clear obstetric indications) [group 1] were compared with pregnant women with prior CS who had spontaneous onset of labor (SOL) [group 2], with respect to incidence of vaginal delivery, CS, duration of labor, and various maternal and fetal outcomes. Results During the study period, 72 women received mifepristone (group 1) for IOL and 346 had SOL (group 2). In group 1 after mifepristone administration, 40 (55.6?%) women had labor onset, and 24 (33.3?%) women had cervical ripening (Bishop Score?≥?8) within 48?h. There were no statistically significant differences with respect to duration of labor ( p value: 0.681), mode of delivery (i.e., normal delivery or CS— p value: 0.076 or 0.120, respectively), or maternal (blood loss or scar dehiscence/rupture uterus), or fetal outcomes (NICU admission) compared to women with previous CS with SOL (group 2). However, the need of oxytocin ( p value 0.020) and dose of oxytocin requirement ( p value 0.008) were more statistically significant in group 1. Conclusion Mifepristone may be considered as an agent for IOL in women with prior CS.
机译:目的探讨“米非司酮”在有剖宫产术(CS)的孕妇引产(IOL)中的作用。方法在这项回顾性研究中,将所有接受过米非司酮口服(400毫克)IOL(根据明确的产科指征)[CS]的先前CS孕妇与自发分娩(CS)的先前CS孕妇进行比较。 )[第2组],关于阴道分娩的发生率,CS,分娩持续时间以及各种母婴结局。结果在研究期间,有72名妇女接受米非司酮(第1组)治疗IOL,有346名患有SOL(第2组)。在服用米非司酮后的第1组中,有40名(55.6%)的妇女开始分娩,而24名(33.3%)的妇女在48小时内出现了宫颈成熟(BishopScore≥8)。分娩持续时间(p值:0.681),分娩方式(即正常分娩或CS-p值:分别为0.076或0.120)或产妇(失血或疤痕裂开/破裂)无统计学差异。子宫)或胎儿结局(NICU入院)与先前曾患有SOL的CS患者(第2组)相比。但是,在第1组中,对催产素的需要(p值0.020)和催产素的需要剂量(p值0.008)在统计学上更为显着。结论结论米非司酮可以被认为是患有CS的女性的IOL药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号